This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.

This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.

The study will collect data from participants via the questionnaire developed by the research team. This study will be conducted in two stages. Stage 1 is the study design phase (i.e., qualitative stage and questionnaire development), which includes the development of the questionnaire, identification of key attributes and levels for the Discrete Choice Experiment (DCE), creation of hypothetical patient profiles to explore high-risk factors in physician decision-making beyond the DCE, as well as questionnaire programming, internal review, pilot testing, revisions, and finalization. Stage 2 involves the implementation of the quantitative survey using the finalized questionnaire and the subsequent data analysis to generate insights into treatment preferences.

Inclusion Criteria:

The following inclusion criteria must be met in order to be enrolled in the stage 1:

Patient:

• Provide informed consent
• 18 years or older
• Diagnosed with stage IV NSCLC
• Currently receiving or previously received 1L EGFR-TKI treatment
• Without communication barrier
• Do not exhibit signs of cognitive impairment that would prevent participation in an interview, as informally assessed during screening by the recruiter

Physician:

• Provide informed consent
• Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
• Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
• Holding the title of associate chief physician or higher

The following inclusion criteria must be met in order to be enrolled in the stage 2:

Patient:

• Provide informed consent
• 18 years or older
• Diagnosed with stage IV NSCLC
• Currently receiving or previously received 1L EGFR-TKI treatment
• Without communication barrier
• Do not exhibit signs of cognitive impairment that would prevent participation in a survey, as informally assessed during screening by the recruiter

Physician:

• Provide informed consent
• Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
• Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
• Holding the title of attending physician or higher

Exclusion Criteria:

Not applicable.

The study population will include patients receiving or who have received 1L EGFR-TKI treatment for stage IV NSCLC and physicians who have experience in the treatment and management of stage IV NSCLC patients with 1L EGFR-TKI. To improve the sample representativeness and generalizability, some soft quotas may be applied during sampling. All the participants who met inclusion criteria will be included.

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.